Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study
- Published on 03/11/2025
- Reading time: 5 min.
Shima Yusuke , Yoshida Hironori , Suminaga Keiichiro , Yoshida Hiroshi , Hashimoto Kentaro , Ogimoto Tatsuya , Hosoya Kazutaka , Ajimizu Hitomi , Funazo Tomoko , Nomizo Takashi , Ozasa Hiroaki , Hirai Toyohiro
https://ror.org/02kpeqv85 Department of Respiratory Medicine, Graduate School of Medicine Kyoto University 54 Kawaharacho, Shogoin, Sakyo-ku 606-8507 Kyoto Japan
Abstract
Background Pemetrexed is a key treatment for non-small-cell lung cancer (NSCLC), and its usage is increasing. However, owing to treatment-related fatality in a patient with severe renal impairment observed during an initial clinical trial, such patients were excluded from further studies. Consequently, data on the safety and efficacy of pemetrexed in these patients are limited. This study aimed to assess the use of pemetrexed in this patient group in a clinical setting.
Methods...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
